Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
A. D'Arienzo(University of Naples Federico II), Filippo Montemurro(Roche (Switzerland)), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), Martina Pagliuca(Institut Gustave Roussy), Annarita Verrazzo(Scuola Superiore Meridionale), Mario Giuliano(Regione Campania), Martina Viggiani(Fribourg Development Agency), Lucia Del Mastro(Ospedale Policlinico San Martino), Fabiana Napolitano(Harold C. Simmons Comprehensive Cancer Center), Sara Parola, Fabio Puglisi(University of Udine)
Cited by 90
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830